Hyaluronidase (human recombinant): all 77 studies that test it
Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.
- A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)Not yet recruitingNCT07760818Phase 2
- A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of CareNot yet recruitingNCT07742527Phase 1
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.RecruitingNCT07596849Phase 3
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' DiseaseRecruitingNCT07570316Phase 3
- A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy SubjectsNot yet recruitingNCT07484893Phase 1
- A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)RecruitingNCT06909214Phase 4
- Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm StudyRecruitingNCT06455748Not applicable
- A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisRecruitingNCT06392386Phase 2/3
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory MyopathyEnrolling by invitationNCT05979441Phase 3
- A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsRecruitingNCT05418868Phase 1
- A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsActive, not recruitingNCT06101134Phase 2Results posted
- A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous PemphigoidTerminatedNCT05681481Phase 3Results posted
- Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult VolunteersCompletedNCT05396742Phase 1Results posted
- A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult ParticipantsCompletedNCT05291520Phase 1Results posted
- A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous PemphigoidCompletedNCT05267600Phase 2/3Results posted
- Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia GravisCompletedNCT04818671Phase 3Results posted
- Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia GravisCompletedNCT04735432Phase 3Results posted
- FT538 in Combination With Daratumumab in AML Acute Myeloid LeukemiaCompletedNCT04714372Phase 1Results posted
- A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaCompletedNCT04687072Phase 3Results posted
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)TerminatedNCT04598477Phase 3Results posted
- A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)CompletedNCT04598451Phase 3Results posted
- A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)CompletedNCT03656718Phase 1/2Results posted
- Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)CompletedNCT03538626Phase 1Results posted
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)TerminatedNCT03281369Phase 1/2Results posted
- Effects of Subcutaneous Hyaluronidase Administration on Psoriatic PlaquesCompletedNCT01987609Phase 2Results posted
- Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With CancerTerminatedNCT01928030Phase 1/2Results posted
- CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)CompletedNCT01848990Phase 4Results posted
- Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema AttacksCompletedNCT01756157Phase 2Results posted
- Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human HyaluronidaseCompletedNCT01526733Phase 4Results posted
- Tolerability and Safety of IGI, 10% With rHuPH20 in PIDDCompletedNCT01485796Phase 2/3Results posted
- A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human HyaluronidaseCompletedNCT01426763Phase 2Results posted
- Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)CompletedNCT01275131Phase 1Results posted
- Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in PediatricsCompletedNCT01139294Phase 4Results posted
- Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)TerminatedNCT01116102Phase 4Results posted
- A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs AloneCompletedNCT00979875Phase 1Results posted
- Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact DermatitisCompletedNCT00928447Phase 2Results posted
- Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)CompletedNCT00916357Phase 2Results posted
- Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes MellitusCompletedNCT00883558Phase 2Results posted
- Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro AloneCompletedNCT00862849Phase 1Results posted
- Gammagard Liquid and rHuPH20 in PIDCompletedNCT00814320Phase 3Results posted
- Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant HyaluronidaseCompletedNCT00807885Phase 4Results posted
- Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes MellitusCompletedNCT00774800Phase 2Results posted
- Subcutaneous Rehydration Compared to Intravenous RehydrationCompletedNCT00773175Phase 4Results posted
- EASI Access II --- Follow-up Study to the EASI Access TrialCompletedNCT00740727Phase 1Results posted
- Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)CompletedNCT00656370Phase 4Results posted
- Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder CancerCompletedNCT00318643Phase 1/2Results posted
- A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20Active, not recruitingNCT07792941Phase 1
- A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's SyndromeActive, not recruitingNCT06684847Phase 3
- A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic SclerosisActive, not recruitingNCT06655155Phase 2
- A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SCCompletedNCT06637072Phase 4
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisActive, not recruitingNCT06558279Phase 3
- A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy ParticipantsCompletedNCT06511570Phase 1
- A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.TerminatedNCT06307626Phase 3
- A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye DiseaseTerminatedNCT06307613Phase 3
- A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)Active, not recruitingNCT05996471Phase 2
- A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.WithdrawnNCT05205252Phase 1/2
- Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy SubjectsCompletedNCT04920370Phase 1
- A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaActive, not recruitingNCT04812925Phase 3
- A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy VolunteersCompletedNCT04564066Phase 1
- SAD and MAD Study With IV and SC Doses of ARGX-117CompletedNCT04532125Phase 1
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)Active, not recruitingNCT04280718Phase 2
- Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy SubjectsCompletedNCT04073589Phase 1
- S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationActive, not recruitingNCT04071457Phase 3
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1
- A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic CancerTerminatedNCT03481920Early Phase 1
- PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic CancerTerminatedNCT02910882Phase 2
- HyQvia in Multifocal Motor NeuropathyStatus unknownNCT02885259Not applicable
- The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal FillersCompletedNCT02654522Phase 1
- A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02519452Phase 1
- Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy VolunteersCompletedNCT01572012Phase 1
- Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)WithdrawnNCT01120431Phase 4
- Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate AloneCompletedNCT00807963Phase 1
- Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder CancerCompletedNCT00782587Phase 1
- Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV SubcutaneouslyCompletedNCT00782106Phase 1/2
- INFUSE Morphine StudyCompletedNCT00593281Phase 3
- A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human HyaluronidaseCompletedNCT00435604Phase 1
- A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer SubjectsCompletedNCT00311519Phase 4